{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:19:42Z","timestamp":1787833182142,"version":"build-2784847793"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.anai.2026.07.014","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:06:09Z","timestamp":1784559969000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of tezepelumab for chronic rhinosinusitis with nasal polyps by eosinophilic endotype"],"prefix":"10.1016","author":[{"given":"Shigeharu","family":"Fujieda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyoshi","family":"Otori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3530-7124","authenticated-orcid":false,"given":"Tadataka","family":"Yabuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Marchese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhia S.","family":"Ponnarambil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Lipworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.anai.2026.07.014_bib0001","first-page":"194","article-title":"EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"issue":"1","key":"10.1016\/j.anai.2026.07.014_bib0002","doi-asserted-by":"crossref","first-page":"uxaf041","DOI":"10.1093\/cei\/uxaf041","article-title":"Thymic stromal lymphopoietin as a therapeutic target in patients with chronic rhinosinusitis and nasal polyps","volume":"219","author":"Peters","year":"2025","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.07.014_bib0003","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.anai.2019.12.001","article-title":"Biologics in chronic rhinosinusitis with nasal polyposis","volume":"124","author":"Laidlaw","year":"2020","journal-title":"Ann Allergy Asthma Immunol."},{"issue":"6","key":"10.1016\/j.anai.2026.07.014_bib0004","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1164\/rccm.201412-2278OC","article-title":"Cytokines in chronic rhinosinusitis. Role in eosinophilia and aspirin-exacerbated respiratory disease","volume":"192","author":"Stevens","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.anai.2026.07.014_bib0005","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2026.07.014_bib0006","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12016-021-08844-7","article-title":"Eosinophils in the field of nasal polyposis: towards a better understanding of biologic therapies","volume":"62","author":"Vanderhaegen","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.anai.2026.07.014_bib0007","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of disease in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"J Asthma Allergy"},{"issue":"suppl S29","key":"10.1016\/j.anai.2026.07.014_bib0008","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"issue":"suppl 1","key":"10.1016\/j.anai.2026.07.014_bib0009","first-page":"S22","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis","volume":"6","author":"Orlandi","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"issue":"3","key":"10.1016\/j.anai.2026.07.014_bib0010","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/lary.26391","article-title":"Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis","volume":"127","author":"DeConde","year":"2017","journal-title":"Laryngoscope"},{"issue":"3","key":"10.1016\/j.anai.2026.07.014_bib0011","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3950\/jibiinkoka.98.402","article-title":"Indications for endoscopic sinus surgery. A clinical study on patients with a poor post-operative course [in Japanese]","volume":"98","author":"Fukami","year":"1995","journal-title":"Nihon Jibiinkoka Gakkai Kaiho"},{"issue":"2","key":"10.1016\/j.anai.2026.07.014_bib0012","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jaci.2014.07.011","article-title":"Mucin 1 downregulation associates with corticosteroid resistance in chronic rhinosinusitis with nasal polyps","volume":"135","author":"Milara","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.07.014_bib0013","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s12325-025-03120-y","article-title":"Real-world outcomes following biologic initiation in US patients with chronic rhinosinusitis with nasal polyps","volume":"42","author":"Peters","year":"2025","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.anai.2026.07.014_bib0014","doi-asserted-by":"crossref","first-page":"441","DOI":"10.7248\/jjrhi1982.38.4_441","article-title":"Classification of chronic sinusitis on the basis of eosinophil infiltration as an additional factor: a histological and immunohistological study [in Japanese]","volume":"38","author":"Fukami","year":"1999","journal-title":"Nihon Bika Gakkai Kaishi"},{"key":"10.1016\/j.anai.2026.07.014_bib0015","first-page":"195","article-title":"Eosinophilic sinusitis [in Japanese]","volume":"44","author":"Haruna","year":"2001","journal-title":"Oto-rhino-laryngol Tokyo"},{"issue":"8","key":"10.1016\/j.anai.2026.07.014_bib0016","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/all.12644","article-title":"Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study","volume":"70","author":"Tokunaga","year":"2015","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.anai.2026.07.014_bib0017","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.alit.2019.12.004","article-title":"Serum IgG4 as a biomarker reflecting pathophysiology and post-operative recurrence in chronic rhinosinusitis","volume":"69","author":"Oka","year":"2020","journal-title":"Allergol Int"},{"issue":"2","key":"10.1016\/j.anai.2026.07.014_bib0018","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jaci.2022.10.026","article-title":"The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis","volume":"151","author":"Rank","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2026.07.014_bib0019","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/all.14809","article-title":"Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"issue":"10209","key":"10.1016\/j.anai.2026.07.014_bib0020","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (Liberty NP SINUS-24 and Liberty NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.anai.2026.07.014_bib0021","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2026.07.014_bib0022","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"22","key":"10.1016\/j.anai.2026.07.014_bib0023","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2026.07.014_bib0024","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4168\/aair.2011.3.3.186","article-title":"Increased expression and role of thymic stromal lymphopoietin in nasal polyposis","volume":"3","author":"Kimura","year":"2011","journal-title":"Allergy Asthma Immunol Res"},{"issue":"3","key":"10.1016\/j.anai.2026.07.014_bib0025","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jaci.2013.04.005","article-title":"Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis","volume":"132","author":"Nagarkar","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2026.07.014_bib0026","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.jaip.2025.04.043","article-title":"Reappraisal of biologic efficacy from phase 3 trials in refractory chronic rhinosinusitis and nasal polyps","volume":"13","author":"Lipworth","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"10.1016\/j.anai.2026.07.014_bib0027","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.anai.2026.07.014_bib0028","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1177\/00034894231177769","article-title":"Psychometric validation and meaningful change thresholds of the new nasal polyposis symptom diary","volume":"132","author":"Shih","year":"2023","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"5","key":"10.1016\/j.anai.2026.07.014_bib0029","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4168\/aair.2018.10.5.490","article-title":"Two-track medical treatment strategy according to the clinical scoring system for chronic rhinosinusitis","volume":"10","author":"Kim","year":"2018","journal-title":"Allergy Asthma Immunol Res"},{"issue":"9","key":"10.1016\/j.anai.2026.07.014_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.70095","article-title":"Characterization of chronic rhinosinusitis patients based on markers of type 2 inflammation: findings from the European CRS Outcome Registry (CHRINOSOR)","volume":"15","author":"Cavaliere","year":"2025","journal-title":"Clin Transl Allergy"},{"issue":"11","key":"10.1016\/j.anai.2026.07.014_bib0031","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1017\/S0022215123000853","article-title":"Phenotypic associations of medical polypectomy and revision surgery following endoscopic sinus surgery: a retrospective study of a single-centre experience in Scotland","volume":"137","author":"Misirovs","year":"2023","journal-title":"J Laryngol Otol"},{"issue":"2","key":"10.1016\/j.anai.2026.07.014_bib0032","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/lary.29888","article-title":"Estimating clinically meaningful change of efficacy outcomes in inadequately controlled chronic rhinosinusitis with nasal polyposis","volume":"132","author":"Han","year":"2022","journal-title":"Laryngoscope"},{"issue":"19","key":"10.1016\/j.anai.2026.07.014_bib0033","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.anai.2026.07.014_bib0034","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1165\/rcmb.2025-0281OC","article-title":"Thymic stromal lymphopoietin promotes ozone-induced inflammation in the airway","volume":"74","author":"Tashiro","year":"2026","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"10.1016\/j.anai.2026.07.014_bib0035","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1084\/jem.20062211","article-title":"Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells","volume":"204","author":"Allakhverdi","year":"2007","journal-title":"J Exp Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626003522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626003522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:38:35Z","timestamp":1787830715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626003522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"alternative-id":["S1081120626003522"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.07.014","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of tezepelumab for chronic rhinosinusitis with nasal polyps by eosinophilic endotype","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}